-
Something wrong with this record ?
Expression of glutamate carboxypeptidase II in human brain
Sácha P, Zámecník J, Barinka C, Hlouchová K, Vícha A, Mlcochová P, Hilgert I, Eckschlager T, Konvalinka J
Language English Country United States
- MeSH
- Enzyme Activation genetics MeSH
- Antigens, Surface analysis immunology metabolism MeSH
- Astrocytes enzymology MeSH
- Dipeptides metabolism MeSH
- Financing, Organized MeSH
- Glutamate Carboxypeptidase II analysis immunology metabolism MeSH
- Immunohistochemistry methods MeSH
- Glutamic Acid biosynthesis MeSH
- Middle Aged MeSH
- Humans MeSH
- Epitope Mapping methods MeSH
- Models, Molecular MeSH
- Brain anatomy & histology enzymology MeSH
- Antibodies immunology MeSH
- Radioligand Assay methods MeSH
- Recombinant Fusion Proteins metabolism MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Protein Structure, Tertiary genetics MeSH
- Blotting, Western MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
Glutamate carboxypeptidase II (GCPII) is a transmembrane glycoprotein expressed in various tissues. When expressed in the brain it cleaves the neurotransmitter N-acetylaspartylglutamate (NAAG), yielding free glutamate. In jejunum it hydrolyzes folylpoly-gamma-glutamate, thus facilitating folate absorption. The prostate form of GCPII, known as prostate specific membrane antigen (PSMA), is an established cancer marker. The NAAG-hydrolyzing activity of GCPII has been implicated in a number of pathological conditions in which glutamate is neurotoxic (e.g. amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, epilepsy, schizophrenia, and stroke). Inhibition of GCPII was shown to be neuroprotective in tissue culture and in animal models. GCPII is therefore an interesting putative therapeutic target. However, only very limited and controversial data on the expression and localization of GCPII in human brain are available. Therefore, we set out to analyze the activity and expression of GCPII in various compartments of the human brain using a radiolabeled substrate of the enzyme and the novel monoclonal antibody GCP-04, which recognizes an epitope on the extracellular portion of the enzyme and is more sensitive to GCPII than to the homologous GCPIII. We show that this antibody is more sensitive in immunoblots than the widely used antibody 7E11. By Western blot, we show that there are approximately 50-300 ng of GCPII/mg of total protein in human brain, depending on the specific area. Immunohistochemical analysis revealed that astrocytes specifically express GCPII in all parts of the brain. GCPII is enzymatically active and the level of activity follows the expression pattern. Using pure recombinant GCPII and homologous GCPIII, we conclude that GCPII is responsible for the majority of overall NAAG-hydrolyzing activity in the human brain.
References provided by Crossref.org
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07527758
- 003
- CZ-PrNML
- 005
- 20111210144004.0
- 008
- 090824s2007 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1016/j.neuroscience.2006.10.022 $2 doi
- 035 __
- $a (PubMed)17150306
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Šácha, Pavel $7 xx0110867
- 245 10
- $a Expression of glutamate carboxypeptidase II in human brain / $c Sácha P, Zámecník J, Barinka C, Hlouchová K, Vícha A, Mlcochová P, Hilgert I, Eckschlager T, Konvalinka J
- 314 __
- $a Department of Biochemistry, Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n.2, Prague 6, 16610 Czech Republic
- 520 9_
- $a Glutamate carboxypeptidase II (GCPII) is a transmembrane glycoprotein expressed in various tissues. When expressed in the brain it cleaves the neurotransmitter N-acetylaspartylglutamate (NAAG), yielding free glutamate. In jejunum it hydrolyzes folylpoly-gamma-glutamate, thus facilitating folate absorption. The prostate form of GCPII, known as prostate specific membrane antigen (PSMA), is an established cancer marker. The NAAG-hydrolyzing activity of GCPII has been implicated in a number of pathological conditions in which glutamate is neurotoxic (e.g. amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, epilepsy, schizophrenia, and stroke). Inhibition of GCPII was shown to be neuroprotective in tissue culture and in animal models. GCPII is therefore an interesting putative therapeutic target. However, only very limited and controversial data on the expression and localization of GCPII in human brain are available. Therefore, we set out to analyze the activity and expression of GCPII in various compartments of the human brain using a radiolabeled substrate of the enzyme and the novel monoclonal antibody GCP-04, which recognizes an epitope on the extracellular portion of the enzyme and is more sensitive to GCPII than to the homologous GCPIII. We show that this antibody is more sensitive in immunoblots than the widely used antibody 7E11. By Western blot, we show that there are approximately 50-300 ng of GCPII/mg of total protein in human brain, depending on the specific area. Immunohistochemical analysis revealed that astrocytes specifically express GCPII in all parts of the brain. GCPII is enzymatically active and the level of activity follows the expression pattern. Using pure recombinant GCPII and homologous GCPIII, we conclude that GCPII is responsible for the majority of overall NAAG-hydrolyzing activity in the human brain.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protilátky $x imunologie $7 D000906
- 650 _2
- $a antigeny povrchové $x analýza $x imunologie $x metabolismus $7 D000954
- 650 _2
- $a astrocyty $x enzymologie $7 D001253
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a mozek $x anatomie a histologie $x enzymologie $7 D001921
- 650 _2
- $a dipeptidy $x metabolismus $7 D004151
- 650 _2
- $a aktivace enzymů $x genetika $7 D004789
- 650 _2
- $a mapování epitopu $x metody $7 D018604
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glutamátkarboxypeptidasa II $x analýza $x imunologie $x metabolismus $7 D043425
- 650 _2
- $a kyselina glutamová $x biosyntéza $7 D018698
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $x metody $7 D007150
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a terciární struktura proteinů $x genetika $7 D017434
- 650 _2
- $a radioligandová zkouška $x metody $7 D011869
- 650 _2
- $a rekombinantní fúzní proteiny $x metabolismus $7 D011993
- 700 1_
- $a Zámečník, Josef, $d 1974- $7 xx0037787
- 700 1_
- $a Bařinka, Cyril $7 xx0126049
- 700 1_
- $a Hlouchová, Klára. $7 xx0270848
- 700 1_
- $a Vícha, Aleš, $d 1971- $7 xx0116880
- 700 1_
- $a Mlčochová, Petra $7 xx0127960
- 700 1_
- $a Hilgert, Ivan $7 xx0074005
- 700 1_
- $a Eckschlager, Tomáš, $d 1956- $7 jn20000400613
- 700 1_
- $a Konvalinka, Jan, $d 1963- $7 mzk2004208597
- 773 0_
- $w MED00003505 $t Neuroscience $g Roč. 144, č. 4 (2007), s. 1361-1372 $x 0306-4522
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090824163150 $b ABA008
- 991 __
- $a 20111103094327 $b ABA008
- 999 __
- $a ok $b bmc $g 672788 $s 532033
- BAS __
- $a 3
- BMC __
- $a 2007 $b 144 $c 4 $d 1361-1372 $i 0306-4522 $m Neuroscience $x MED00003505
- LZP __
- $a 2009-B4/vtme